(RTTNews) - Monday, Estrella Immunopharma (ESLA), a clinical-stage biopharmaceutical company for treating cancer and autoimmune diseases, appointed Cynthia Pussinen as the Chief Executive Officer and Board Chair, effective October 25, 2026. She succeeds Cheng Liu, who will become
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.